EQS.PA Equasens S. A.
- Market cap
- EUR 418M
- P/E
- 10.7x
- P/B
- 1.67x
- ROE
- 30.4%
- Dividend yield
- 2.49%
- Fundamental score
- 4.3/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is EQS.PA undervalued?
Graham numberEQS.PA trades 10.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Equasens S. A. fundamental analysis
9 of 11 checks passedROE 2/2
ROE surpassing expectations (26.59%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.
ROA 2/2
The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.
PBV 0/2
The stock's high Price-to-Book Value (P/BV) ratio (4.59x) suggests it's overvalued, potentially making it an expensive investment.
DER 2/2
The stock has a minimal amount of debt (10%) relative to its ownership, showcasing a strong financial position and lower risk for investors.
Revenue Growth 2/2
Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.
Net Profit Growth 2/2
The net profit of this company has steadily increased over the last five years, showcasing a favorable financial performance and making it an enticing option for investors seeking growth potential.
Assets Growth 2/2
This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.
Graham Number 0/1
Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.
Dividend Growth 2/2
Investors can be encouraged by the company's strong dividend growth over the past five years, highlighting its ability to generate consistent returns and provide an attractive investment opportunity.
Dividend 2/2
With a solid track record of dividend payments over the past five years, the company has established itself as a dependable choice for investors seeking consistent income.
Buffet Intrinsic Value 1/1
The company's stock presents an enticing opportunity as it appears undervalued (311) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Equasens S. A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Equasens S. A.
Equasens Société anonyme provides healthcare IT solutions in France, Italy, Belgium, Germany, the United Kingdom, and internationally. The company operates through Sales of Configurations and Hardware, Maintenance Services and Subscriptions, and Software and Services segments. The company engages in publishing and distribution of pharmacy, practice, management software and related offerings for pharmacies, medical-social establishments, doctors, and medical auxiliaries; dist…
Full company profileEquasens S. A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Equasens S. A. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 128M | 130M | 148M | 159M | 172M | 193M | 214M | 220M | 217M | 237M | 498M |
| Gross Profit | 37.9M | 37.3M | 42.0M | 44.5M | 49.4M | 53.8M | 59.0M | 56.7M | 47.1M | 49.7M | 100M |
| Operating Income | 31.4M | 34.3M | 38.9M | 40.8M | 46.7M | 50.3M | 56.2M | 55.4M | 44.6M | 47.7M | 93.6M |
| EBITDA | 34.9M | 38.5M | 44.1M | 48.3M | 55.8M | 62.2M | 68.5M | 68.6M | 59.4M | 65.3M | 132M |
| Net Income | 20.6M | 23.2M | 25.4M | 28.4M | 30.7M | 39.1M | 46.2M | 47.0M | 36.2M | 39.3M | 75.9M |
| EPS | 1.36 | 1.53 | 1.68 | 1.89 | 2.04 | 2.58 | 3.05 | 3.13 | 2.39 | 2.62 | 4.81 |
| Balance Sheet | |||||||||||
| Total Assets | 151M | 178M | 224M | 258M | 296M | 330M | 351M | 394M | 398M | 439M | 451M |
| Total Liabilities | 47.0M | 73.2M | 107M | 126M | 147M | 165M | 154M | 166M | 157M | 176M | 190M |
| Shareholders' Equity | 102M | 102M | 114M | 128M | 143M | 159M | 190M | 219M | 232M | 252M | 250M |
| Cash & Short-term Investments | 55.2M | 55.7M | 61.3M | 50.6M | 63.3M | 64.8M | 68.0M | 54.7M | 40.2M | 87.1M | 69.0M |
| Total Debt | 10.4M | 16.9M | 43.2M | 49.0M | 69.0M | 84.1M | 66.5M | 69.3M | 48.5M | 53.8M | 57.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 22.6M | 27.2M | 28.7M | 40.7M | 47.2M | 47.5M | 57.0M | 61.6M | 47.6M | 59.2M | 67.0M |
| Capital Expenditure | 6.02M | 7.70M | 11.1M | 17.0M | 19.7M | 10.4M | 10.2M | 18.4M | 11.6M | 12.1M | 26.7M |
| Free Cash Flow | 16.6M | 19.5M | 17.7M | 23.7M | 27.5M | 37.1M | 46.8M | 43.2M | 35.9M | 47.1M | 40.3M |
| Ratios | |||||||||||
| ROE | 20.2% | 22.6% | 22.3% | 22.3% | 21.4% | 24.6% | 24.4% | 21.5% | 15.7% | 15.6% | 30.4% |
| ROA | 13.6% | 13.0% | 11.4% | 11.0% | 10.4% | 11.9% | 13.2% | 11.9% | 9.1% | 9.0% | 16.8% |
| Net Profit Margin | 16.0% | 17.9% | 17.1% | 17.9% | 17.9% | 20.3% | 21.6% | 21.4% | 16.7% | 16.6% | 15.2% |
| Debt to Equity | 0.10x | 0.16x | 0.38x | 0.38x | 0.48x | 0.53x | 0.35x | 0.32x | 0.21x | 0.21x | 0.23x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Equasens S. A. dividends
- Dividend yield
- 2.49%
- Forward dividend
- 1.40 EUR
- Payout ratio
- 26.4%
- Ex-dividend date
- Jul 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 10.4M | 0.69 | 26.4% |
| 2024 | EUR 18.8M | 1.24 | 51.9% |
| 2023 | EUR 17.3M | 1.15 | 36.7% |
| 2022 | EUR 15.8M | 1.04 | 34.1% |
| 2021 | EUR 14.3M | 0.94 | 36.5% |
| 2020 | EUR 13.5M | 0.90 | 44.1% |
| 2019 | EUR 12.8M | 0.85 | 44.9% |
| 2018 | EUR 11.2M | 0.74 | 44.1% |
| 2017 | EUR 9.73M | 0.64 | 42.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Aug 5, 2015.
Who owns Equasens S. A.
- Insiders 67.09%
- Institutions 11.47%
- Public & others 21.45%
- Shares outstanding 15.0M
- Free float 15.0M
Equasens S. A. company profile
- Company name
- Equasens S. A.
- Ticker
- EQS.PA
- ISIN
- FR0012882389
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 1,500
- Fiscal year end
- December
- Address
- 5 Allée de Saint-Cloud, Villers-lès-Nancy, France, 54600
- Phone
- 33 3 83 15 95 95
- Website
- equasens.com
About Equasens S. A.
Equasens Société anonyme provides healthcare IT solutions in France, Italy, Belgium, Germany, the United Kingdom, and internationally. The company operates through Sales of Configurations and Hardware, Maintenance Services and Subscriptions, and Software and Services segments. The company engages in publishing and distribution of pharmacy, practice, management software and related offerings for pharmacies, medical-social establishments, doctors, and medical auxiliaries; distribution of computer equipment, turnkey installation and training; after-sales services, and telephone support and maintenance; and data backup, intermediation, and vocational training services. It also provides medical remote monitoring systems, develops a structured medical speech recognition solution, and designs and manufactures connected electronic devices and equipment, as well as offers interoperability solutions. In addition, the company offers financing platform to facilitate multi-donor management, and financing solutions for leased assets for healthcare professionals and others. It serves healthcare facilities and healthcare professionals. The company was incorporated in 1996 and is headquartered in Villers-lès-Nancy, France. Equasens Société anonyme operates as a subsidiary of Marque Verte Sante.
Equasens S. A. management
8- Mr. Denis SupplissonCEO & Director · born 1969
- Mr. Grégoire De RotalierDeputy CEO, Deputy MD, Director of Healthcare, Medical & Social Software Division and Director · born 1970
- Mr. Dominique PautratChairman of the Board · born 1965
- Ms. Frederique SchmidtGroup Chief Administrative & Financial Officer
- Ms. Noelle StouligHead of Communications
- Ms. Sabrina GharbiChief Human Resources Officer
- Mr. Dominique GoursaudHead of the Medical Solutions Division
- Mr. Francois-Pierre MarquierDeputy CEO, Director of Pharmagest Division & Director